Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285744 | 0.99 | PTPN1 (0.47) | PTPN1BCHEHRH3SIGMAR1LTA4H | |
| SCHEMBL6283355 | 0.89 | PTPN1 (0.50) | PTPN1BCHEHRH3SIGMAR1LTA4H | |
| SCHEMBL6285254 | 0.89 | PTPN1 (0.50) | PTPN1BCHEHRH3SIGMAR1LTA4H | |
| SCHEMBL6282841 | 0.88 | PTPN1 (0.49) | PTPN1BCHEHRH3SIGMAR1LTA4H | |
| SCHEMBL6279694 | 0.83 | ESR1 (0.52) | PTPN1HTR2A | |
| SCHEMBL6279184 | 0.82 | PTPN1 (0.73) | PTPN1 | |
| SCHEMBL6278957 | 0.82 | ESR1 (0.50) | PTPN1HRH3HTR2A | |
| SCHEMBL6286719 | 0.81 | PTPN1 (0.49) | PTPN1BCHEHRH3LTA4HEPHX2 | |
| SCHEMBL6283361 | 0.81 | PTPN1 (0.49) | PTPN1BCHEHRH3LTA4HEPHX2 | |
| SCHEMBL6287247 | 0.81 | PTPN1 (0.67) | PTPN1BCHEHRH3LTA4HEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | PTPN1 2/4885BCHE 4082/4885HRH3 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.